Drug Search Results
More Filters [+]

MK-4074

Alternative Names: mk-4074, mk4074, mk 4074
Latest Update: 2024-01-09
Latest Update Note: PubMed Publication

Product Description

Merck was developing mk-4074, an oral ACC Inhibitor for Non-alcoholic Fatty Liver Disease

Mechanisms of Action: ACC Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for MK-4074

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Non-alcoholic Fatty Liver Disease|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-4074-008

P1

Completed

Non-alcoholic Fatty Liver Disease|Liver Diseases, Alcoholic|Fatty Liver, Alcoholic

2012-09-18

Recent News Events